X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1390) 1390
Publication (110) 110
Patent (34) 34
Book Review (8) 8
Book Chapter (3) 3
Magazine Article (3) 3
Conference Proceeding (2) 2
Book / eBook (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (489) 489
gastroenterology & hepatology (412) 412
index medicus (391) 391
gastroenterology and hepatology (318) 318
male (288) 288
female (283) 283
adult (267) 267
crohn's disease (203) 203
middle aged (190) 190
inflammatory-bowel-disease (183) 183
ulcerative colitis (163) 163
inflammatory bowel disease (160) 160
crohns-disease (151) 151
infliximab (140) 140
ulcerative-colitis (115) 115
crohn disease - drug therapy (111) 111
abridged index medicus (109) 109
treatment outcome (109) 109
adolescent (95) 95
aged (92) 92
inflammatory bowel diseases (89) 89
risk factors (86) 86
care and treatment (82) 82
young adult (79) 79
therapy (73) 73
severity of illness index (62) 62
analysis (56) 56
antibodies, monoclonal - therapeutic use (56) 56
remission (56) 56
gastrointestinal diseases (55) 55
crohn disease - diagnosis (53) 53
life sciences (53) 53
remission induction (53) 53
clinical trials (52) 52
colitis, ulcerative - drug therapy (52) 52
follow-up studies (51) 51
immunosuppressive agents - therapeutic use (51) 51
adalimumab (50) 50
maintenance therapy (49) 49
organic chemistry (49) 49
tumor necrosis factor-alpha - antagonists & inhibitors (48) 48
azathioprine (47) 47
double-blind method (47) 47
ibd (47) 47
retrospective studies (45) 45
crohns disease (44) 44
gastrointestinal agents - therapeutic use (44) 44
time factors (44) 44
gastroenterology (43) 43
risk (43) 43
crohn disease - pathology (42) 42
child (41) 41
colitis (41) 41
inflammation (40) 40
management (40) 40
animals (39) 39
c-reactive protein (39) 39
patients (39) 39
quality of life (39) 39
anti-inflammatory agents - therapeutic use (38) 38
crohn disease - genetics (38) 38
endoscopy (38) 38
incidence (38) 38
inflammatory bowel diseases - drug therapy (38) 38
medical research (38) 38
prospective studies (38) 38
intestine (37) 37
medical colleges (37) 37
surgery (37) 37
efficacy (36) 36
rheumatoid-arthritis (36) 36
crohn disease - complications (35) 35
pharmacology & pharmacy (35) 35
prognosis (34) 34
crohn disease - immunology (33) 33
crohn’s disease (33) 33
intestinal mucosa - pathology (33) 33
chemistry (32) 32
induction (32) 32
research (32) 32
diagnosis (31) 31
health aspects (31) 31
medicine, experimental (31) 31
metallurgy (31) 31
mice (31) 31
crohn disease - epidemiology (30) 30
epidemiology (30) 30
prevalence (30) 30
aged, 80 and over (29) 29
antibodies, monoclonal, humanized - therapeutic use (29) 29
cancer (29) 29
chemical sciences (29) 29
colonoscopy (29) 29
crohn disease - surgery (29) 29
recurrence (29) 29
antibodies, monoclonal - adverse effects (28) 28
case-control studies (28) 28
crohn disease - therapy (28) 28
human necessities (28) 28
hygiene (28) 28
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1374) 1374
French (73) 73
German (7) 7
Danish (1) 1
Polish (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10080, pp. 1756 - 1770
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 711 - 721
Journal Article
Gut, ISSN 0017-5749, 05/2017, Volume 66, Issue 5, pp. 839 - 851
ObjectiveVedolizumab is a gut-selective antibody to α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an... 
INFLAMMATORY-BOWEL-DISEASE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | OPPORTUNISTIC INFECTIONS | FOLLOW-UP | RISK | EXPERIENCE | COHORT | INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | ADVERSE EVENTS | MAINTENANCE THERAPY | Tuberculosis - epidemiology | Age Factors | Humans | Middle Aged | Male | Narcotics - therapeutic use | Clostridium Infections - epidemiology | Adrenal Cortex Hormones - therapeutic use | Incidence | Young Adult | Treatment Failure | Infusions, Intravenous - adverse effects | Gastrointestinal Agents - immunology | Adult | Female | Colitis, Ulcerative - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Factors | Sepsis - epidemiology | Chemical and Drug Induced Liver Injury - epidemiology | Randomized Controlled Trials as Topic | Crohn Disease - drug therapy | Gastrointestinal Agents - therapeutic use | Gastrointestinal Agents - adverse effects | Antibodies, Monoclonal, Humanized - immunology | Antibodies, Neutralizing - blood | Leukoencephalopathy, Progressive Multifocal - epidemiology | Neoplasms - epidemiology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drug therapy | Crohn's disease | Ulcerative colitis | Clinical trials | Infections | Malignancy | Patients | Risk factors | Crohns disease | Inflammatory bowel disease | Studies | Tuberculosis | Tumor necrosis factor | Population | Tumor necrosis factor-TNF | TNF inhibitors | Sepsis | Safety | Drug dosages | Tumors | 1506 | Inflammatory Bowel Disease
Journal Article
Gut, ISSN 0017-5749, 02/2013, Volume 62, Issue 2, pp. 201 - 208
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 143, Issue 5, pp. 1207 - 1217.e2
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 699 - 710
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9701, pp. 1617 - 1625
Journal Article